98 related articles for article (PubMed ID: 6252519)
1. [Metabolic changes induced with salmon calcitonin in post-menopausal osteoporosis].
Nuti R; Martini G; Campagna MS; Franci B
Minerva Med; 1980 Sep; 71(31):2221-8. PubMed ID: 6252519
[TBL] [Abstract][Full Text] [Related]
2. [Behavior of urinary excretion of cyclic AMP in post-menopausal osteoporosis during therapy with salmon calcitonin].
Nuti R; Galli M; Righi GA; Turchetti V; Campagna MS; Franci B
Minerva Med; 1982 May; 73(19):1283-9. PubMed ID: 6281691
[TBL] [Abstract][Full Text] [Related]
3. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
Hodsman AB; Fraher LJ
Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
[TBL] [Abstract][Full Text] [Related]
4. Reduced parathyroid hormone response to peroral phosphate in osteoporotic patients.
Ittner J; Dambacher MA; Muff R; Rüegsegger P; Trechsel U; Fischer JA
Miner Electrolyte Metab; 1986; 12(3):199-203. PubMed ID: 3014300
[TBL] [Abstract][Full Text] [Related]
5. Early effects of synthetic bovine parathyroid hormone and synthetic salmon calcitonin on urinary excretion of cyclic AMP, phosphate and calcium in man.
Caniggia A; Gennari C; Vattimo A; Nardi P; Nuti R; Galli M
Calcif Tissue Res; 1976 Apr; (2):209-15. PubMed ID: 177154
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of resistance to the phosphaturic effect of the parathyroid hormone in the hamster.
Knox FG; Preiss J; Kim JK; Dousa TP
J Clin Invest; 1977 Apr; 59(4):675-83. PubMed ID: 14974
[TBL] [Abstract][Full Text] [Related]
7. Calcium and salmon calcitonin in treatment of osteoporosis.
Jowsey J; Riggs BL; Kelly PJ; Hoffman DL
J Clin Endocrinol Metab; 1978 Sep; 47(3):633-9. PubMed ID: 263316
[TBL] [Abstract][Full Text] [Related]
8. [Asu(1,7)E-CT, an analog of eel calcitonin. A comparative study in man with reference to other synthetic calcitonins].
Caniggia A; Nuti R; Vattimo A; Galli M; Turchetti V; Franci B; Martorelli T; Righi G
Minerva Med; 1983 Apr; 74(18):993-1010. PubMed ID: 6087215
[TBL] [Abstract][Full Text] [Related]
9. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Kuntz D; Marie P; Berhel M; Caulin F
Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
[TBL] [Abstract][Full Text] [Related]
10. Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women.
González D; Ghiringhelli G; Mautalen C
Calcif Tissue Int; 1986 Feb; 38(2):71-5. PubMed ID: 3082496
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
12. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of calcitonin and parathyroid extract in man. Studies in hypoparathyroidism.
Haas HG; Dambacher MA; Guncaga J; Lauffenbruger T
J Clin Invest; 1971 Dec; 50(12):2689-702. PubMed ID: 5166965
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of cyclic nucleotides and phosphate in response to parathyroid hormone and calcitonin in man.
Suh SM; Firek AF; Kim DH; Ramanathan S
Pediatr Res; 1981 Oct; 15(10):1359-62. PubMed ID: 6272182
[TBL] [Abstract][Full Text] [Related]
15. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
16. The concept and treatment of osteoporosis.
Rittinghaus EF; Hesch RD; Harms HM; Busch U; Prokop M; Delling G
Exp Gerontol; 1990; 25(3-4):357-65. PubMed ID: 2226671
[TBL] [Abstract][Full Text] [Related]
17. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
18. Plasma immunoreactive N-terminal parathyroid hormone and cyclic AMP and cyclic GMP urinary levels in man after I. M. administration of two different doses of porcine calcitonin.
Vigo PL; Milhaud G; Peracchi M; Girardello R; Ortolani S; Polli EE
Biomedicine; 1980 Dec; 33(8):255-9. PubMed ID: 6260260
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term effects of calcitonin and calcium administration on blood calcium, magnesium and inorganic phosphorus in post menopausal osteoporosis.
Casao E; Elósegui LM; Ibáñez MA; Vidal MD; Cervera P; Escanero JF
J Trace Elem Med Biol; 1995 Oct; 9(3):181-4. PubMed ID: 8605609
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
